Hydroxyethyl starch: putting patient safety first

Intensive Care Med. 2014 Feb;40(2):256-259. doi: 10.1007/s00134-013-3167-6. Epub 2013 Dec 19.

Authors

Julian Bion¹, Rinaldo Bellomo², John Myburgh³, Anders Perner⁴, Konrad Reinhart⁵, Simon Finfer⁶

Affiliations

¹ University of Birmingham, Birmingham, UK. j.f.bion@bham.ac.uk.
² University of Melbourne, Melbourne, Australia.
³ The George Institute for Global Health and the University of New South Wales, Sydney, Australia.
⁴ Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
⁵ Friedrich Schiller University, Jena, Germany.
⁶ Royal North Shore Hospital and The George Institute for Global Health, University of Sydney, Sydney, Australia.

PMID: 24352482
DOI: 10.1007/s00134-013-3167-6

No abstract available

MeSH terms

Europe
Humans
Hydroxyethyl Starch Derivatives / adverse effects*
Patient Safety*
Pharmacovigilance*
Plasma Substitutes / adverse effects*

Substances

Hydroxyethyl Starch Derivatives
Plasma Substitutes